Microbio Co., Ltd.
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
- Conditions
- SepsisSeptic ShockBloodstream Infection
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Microbio Co Ltd
- Target Recruit Count
- 1500
- Registration Number
- NCT06531031
- Locations
- 🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸TriCore Reference Laboratories, Albuquerque, New Mexico, United States
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
- Conditions
- Atopic DermatitisStaphylococcus Aureus
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Microbio Co Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT05092464
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Microbio Co Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT05078567
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Microbio Co Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT04909034
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳E-Da Hospital, Kaohsiung, Taiwan
🇨🇳Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Microbio Co Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT04674839
- Locations
- 🇨🇳
Microbio Group, Taipei, Taiwan
- Prev
- 1
- 2
- Next
News
MS-20 Shows Remarkable Efficacy as Add-on Therapy for Ulcerative Colitis in Clinical Trial
Microbio's postbiotic MS-20 achieved 83.3% clinical remission rate in ulcerative colitis patients when added to standard treatments, compared to 35.7% with placebo, demonstrating statistically significant improvement (p=0.021).